These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35264726)

  • 1. Schizophrenia: a disorder of broken brain bioenergetics.
    Henkel ND; Wu X; O'Donovan SM; Devine EA; Jiron JM; Rowland LM; Sarnyai Z; Ramsey AJ; Wen Z; Hahn MK; McCullumsmith RE
    Mol Psychiatry; 2022 May; 27(5):2393-2404. PubMed ID: 35264726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia Outside the Brain.
    Valença AGF; Smith BJ
    Adv Exp Med Biol; 2022; 1400():53-63. PubMed ID: 35930225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain insulin action: Implications for the treatment of schizophrenia.
    Agarwal SM; Kowalchuk C; Castellani L; Costa-Dookhan KA; Caravaggio F; Asgariroozbehani R; Chintoh A; Graff-Guerrero A; Hahn M
    Neuropharmacology; 2020 May; 168():107655. PubMed ID: 31152767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.
    Boison D; Singer P; Shen HY; Feldon J; Yee BK
    Neuropharmacology; 2012 Mar; 62(3):1527-43. PubMed ID: 21315743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia.
    Bryll A; Skrzypek J; Krzyściak W; Szelągowska M; Śmierciak N; Kozicz T; Popiela T
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32121669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Insights into Psychosis and Antipsychotic Interventions: From Managing Symptoms to Improving Outcomes.
    Sfera A; Imran H; Sfera DO; Anton JJ; Kozlakidis Z; Hazan S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidant treatments for schizophrenia.
    Magalhães PV; Dean O; Andreazza AC; Berk M; Kapczinski F
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008919. PubMed ID: 26848926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
    Condray R; Dougherty GG; Keshavan MS; Reddy RD; Haas GL; Montrose DM; Matson WR; McEvoy J; Kaddurah-Daouk R; Yao JK
    Int J Neuropsychopharmacol; 2011 Jul; 14(6):756-67. PubMed ID: 21275080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic blockade of adenosine A2A receptors induces cognitive impairments and anatomical changes related to psychotic symptoms in mice.
    Moscoso-Castro M; Gracia-Rubio I; Ciruela F; Valverde O
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1227-40. PubMed ID: 27133030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating impaired cognition in schizophrenia.
    Ibrahim HM; Tamminga CA
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1587-94. PubMed ID: 22283754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.
    Liu SK; Fitzgerald PB; Daigle M; Chen R; Daskalakis ZJ
    Biol Psychiatry; 2009 Mar; 65(6):503-9. PubMed ID: 18950746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.
    Pillai A
    Neurosignals; 2008; 16(2-3):183-93. PubMed ID: 18253057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
    Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.